絞り込み

16645

広告

Cost impact of a non-invasive, portable device for patient self-administration of chronic migraine in a UK National Health Service setting.

著者 Brüggenjürgen B , Baker T , Bhogal R , Ahmed F
Springerplus.2016 ; 5(1):1249.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (5view , 0users)
Chronic migraine (CM) is a neurological disorder associated with substantial disability. Botulinum toxin type A (Botox) is an approved and effective preventive treatment option for adult patients with CM. Transcranial magnetic stimulation (TMS) is an alternative treatment device delivering a brief pre-set magnetic pulse used for self-administration by the patient at home. Despite being available in a risk share scheme TMS is perceived to be more costly in the UK. The objective of this study was to analyse the incremental costs of TMS compared to Botox in refractory CM patients both for a UK individual funding request setting as well as for an average UK specialist center setting.
PMID: 27536532 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード